Programmed Cell Death Ligand 1 Expression in Non-Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-control Study.
Clin Lung Cancer
; 19(5): e667-e673, 2018 09.
Article
em En
| MEDLINE
| ID: mdl-29844002
ABSTRACT
BACKGROUND:
Programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) checkpoint inhibitors have demonstrated antitumor activity, and immunohistochemical analysis of PD-L1 expression has been used to identify the response in patients with non-small-cell lung cancer (NSCLC). Recently, considerable interest has ensued toward extending the benefit of these inhibitors to high-risk patients, such as those with NSCLC and interstitial lung disease (ILD). However, no studies have compared PD-L1 expression in NSCLC patients with and without ILD. Therefore, we conducted a case-control study to evaluate PD-L1 expression and stromal CD8+ lymphocyte density in these patients. MATERIALS ANDMETHODS:
The data from patients with pathologic stage I or II NSCLC who had undergone surgery from January 2007 to January 2016 were analyzed.RESULTS:
We identified 62 patients with pathologic stage I or II NSCLC and ILD. We compared these patients with 11-matched cohort. In both groups with and without ILD, approximately 60% were PD-L1+. Tumor cell PD-L1 expression was similar between the groups (median, 1%; interquartile range, 0%-5%; vs. median, 1%; interquartile range, 0%-5%; P = .49). The proportion of patients with positive (≥ 1%) and strongly positive (≥ 50%) PD-L1 expression was also similar between the 2 groups (P = .46 and P = 1.00, respectively). Additionally, the CD8+ lymphocyte density did not differ between patients with and without ILD.CONCLUSION:
PD-L1 expression and stromal CD8+ lymphocyte density were comparable between the NSCLC patients with and without ILD. PD-1 axis inhibitors might be effective for NSCLC patients with ILD.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Carcinoma de Células Escamosas
/
Adenocarcinoma
/
Biomarcadores Tumorais
/
Doenças Pulmonares Intersticiais
/
Carcinoma Pulmonar de Células não Pequenas
/
Antígeno B7-H1
/
Neoplasias Pulmonares
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article